40. 高安動脈炎 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 24 / 薬物数 : 40 - (DrugBank : 18) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 110
薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
AZA
Chinese SLE Treatment And Research Group
2017 Phase 3 NCT03096275 China;
Adalimumab
Shanghai Zhongshan Hospital
2020 Phase 4 NCT04300686 China;
Adalimumab Injection
Chinese SLE Treatment And Research Group
2022 Phase 4 NCT05151848 China;
Anti-thymocyte globulin
Fairview University Medical Center
2000 - NCT00006055 United States;
Autologous Peripheral Blood Stem Cell Transplantation
Fairview University Medical Center
2000 - NCT00006055 United States;
CYC
Chinese SLE Treatment And Research Group
2017 Phase 3 NCT03096275 China;
Clofarabine
Jonsson Comprehensive Cancer Center
2016 Early Phase 1 NCT02925351 United States;
Computed Tomography
Jonsson Comprehensive Cancer Center
2016 Early Phase 1 NCT02925351 United States;
Cyclophosphamide
Fairview University Medical Center
2000 - NCT00006055 United States;
Cyclosporine
Fairview University Medical Center
2000 - NCT00006055 United States;
Digital substraction angiography (DSA)
Shanghai Zhongshan Hospital
2019 - NCT04137614 China;
Drug coated balloon (DCB)
Shanghai Zhongshan Hospital
2019 - NCT04137614 China;
Filgrastim
Fairview University Medical Center
2000 - NCT00006055 United States;
Glucocorticoids
Chinese SLE Treatment And Research Group
2017 Phase 3 NCT03096275 China;
Glucorticoid Taper Regimen
Janssen Pharmaceutical K.K.
2021 Phase 3 NCT04882072 Japan;
Infliximab
Assistance Publique - Hôpitaux de Paris
2020 Phase 2 NCT04564001 -
Ospedale San Raffaele
2017 - NCT03192878 Italy;
Leflunomide
Shanghai Zhongshan Hospital
2016 - NCT03893136 China;
Leflunomide 10mg Tab
Jiang lindi
2016 - NCT02981979 China;
MMF
Chinese SLE Treatment And Research Group
2017 Phase 3 NCT03096275 China;
MTX
Chinese SLE Treatment And Research Group
2017 Phase 3 NCT03096275 China;
Methotrexate Tablets
Shanghai Zhongshan Hospital
2020 Phase 4 NCT04299971 China;
Methylprednisolone
Fairview University Medical Center
2000 - NCT00006055 United States;
Naltrexone Hydrochloride
University of Pennsylvania
2019 Phase 2 NCT03482479 United States;
Placebo
Chugai Pharmaceutical Co., Ltd.
2014 Phase 3 JPRN-JapicCTI-142616 Japan;
Positron Emission Tomography
Jonsson Comprehensive Cancer Center
2016 Early Phase 1 NCT02925351 United States;
Prednisolone
AbbVie
2020 Phase 3 NCT04161898 Japan;Korea, Republic of;Turkey;
Prednisone
Fairview University Medical Center
2000 - NCT00006055 United States;
Prednisone, cyclophosphamide
Chinese Academy of Medical Sciences, Fuwai Hospital
2018 Phase 2/Phase 3 NCT03550781 -
Remicade (anti tumor necrosis factor inhibitor)
Seoul National University Hospital
2015 Phase 2 NCT02457585 Korea, Republic of;
RoActemra 20mg/ml
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
2019 Phase 3 EUCTR2018-003753-13-FR France;
Tocilizumab
Clinical ImmunologySaitama Medical Center, Saitama Medical Universitity
Assistance Publique - Hôpitaux de Paris
2020 Phase 2 NCT04564001 -
2014 Phase 3 NCT02101333 France;
Department of Cardiovascular Medicine Graduate School of Medicine Osaka University
2012 - JPRN-UMIN000007845 Japan;
Department of Rheumatology &
Osaka University
2017 - JPRN-UMIN000025940 Japan;
Osaka Unversity
2014 - JPRN-UMIN000025943 Japan;
Shanghai Zhongshan Hospital
2020 Phase 4 NCT04300686 China;
2016 - NCT03893136 China;
Tocilizumab (MRA-SC)
Chugai Pharmaceutical Co., Ltd.
2014 Phase 3 JPRN-JapicCTI-142616 Japan;
Tofacitinib
Chinese SLE Treatment And Research Group
2022 Phase 4 NCT05151848 China;
Tofacitinib tablet
Shanghai Zhongshan Hospital
2020 Phase 4 NCT04299971 China;
Upadacitinib
AbbVie
2020 Phase 3 NCT04161898 Japan;Korea, Republic of;Turkey;
Ustekinumab
Janssen Pharmaceutical K.K.
2021 Phase 3 NCT04882072 Japan;
Numaguchi Hirotaka
2021 Phase 3 JPRN-jRCT2061210007 Japan;
Yellow Fever vaccine (17D)
University of Sao Paulo General Hospital
2018 - NCT03430388 Brazil;
Chinese SLE Treatment And Research Group
2017 Phase 3 NCT03096275 China;
Adalimumab
Shanghai Zhongshan Hospital
2020 Phase 4 NCT04300686 China;
Adalimumab Injection
Chinese SLE Treatment And Research Group
2022 Phase 4 NCT05151848 China;
Anti-thymocyte globulin
Fairview University Medical Center
2000 - NCT00006055 United States;
Autologous Peripheral Blood Stem Cell Transplantation
Fairview University Medical Center
2000 - NCT00006055 United States;
CYC
Chinese SLE Treatment And Research Group
2017 Phase 3 NCT03096275 China;
Clofarabine
Jonsson Comprehensive Cancer Center
2016 Early Phase 1 NCT02925351 United States;
Computed Tomography
Jonsson Comprehensive Cancer Center
2016 Early Phase 1 NCT02925351 United States;
Cyclophosphamide
Fairview University Medical Center
2000 - NCT00006055 United States;
Cyclosporine
Fairview University Medical Center
2000 - NCT00006055 United States;
Digital substraction angiography (DSA)
Shanghai Zhongshan Hospital
2019 - NCT04137614 China;
Drug coated balloon (DCB)
Shanghai Zhongshan Hospital
2019 - NCT04137614 China;
Filgrastim
Fairview University Medical Center
2000 - NCT00006055 United States;
Glucocorticoids
Chinese SLE Treatment And Research Group
2017 Phase 3 NCT03096275 China;
Glucorticoid Taper Regimen
Janssen Pharmaceutical K.K.
2021 Phase 3 NCT04882072 Japan;
Infliximab
Assistance Publique - Hôpitaux de Paris
2020 Phase 2 NCT04564001 -
Ospedale San Raffaele
2017 - NCT03192878 Italy;
Leflunomide
Shanghai Zhongshan Hospital
2016 - NCT03893136 China;
Leflunomide 10mg Tab
Jiang lindi
2016 - NCT02981979 China;
MMF
Chinese SLE Treatment And Research Group
2017 Phase 3 NCT03096275 China;
MTX
Chinese SLE Treatment And Research Group
2017 Phase 3 NCT03096275 China;
Methotrexate Tablets
Shanghai Zhongshan Hospital
2020 Phase 4 NCT04299971 China;
Methylprednisolone
Fairview University Medical Center
2000 - NCT00006055 United States;
Naltrexone Hydrochloride
University of Pennsylvania
2019 Phase 2 NCT03482479 United States;
Placebo
Chugai Pharmaceutical Co., Ltd.
2014 Phase 3 JPRN-JapicCTI-142616 Japan;
Positron Emission Tomography
Jonsson Comprehensive Cancer Center
2016 Early Phase 1 NCT02925351 United States;
Prednisolone
AbbVie
2020 Phase 3 NCT04161898 Japan;Korea, Republic of;Turkey;
Prednisone
Fairview University Medical Center
2000 - NCT00006055 United States;
Prednisone, cyclophosphamide
Chinese Academy of Medical Sciences, Fuwai Hospital
2018 Phase 2/Phase 3 NCT03550781 -
Remicade (anti tumor necrosis factor inhibitor)
Seoul National University Hospital
2015 Phase 2 NCT02457585 Korea, Republic of;
RoActemra 20mg/ml
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
2019 Phase 3 EUCTR2018-003753-13-FR France;
Tocilizumab
Clinical ImmunologySaitama Medical Center, Saitama Medical Universitity
Assistance Publique - Hôpitaux de Paris
2020 Phase 2 NCT04564001 -
2014 Phase 3 NCT02101333 France;
Department of Cardiovascular Medicine Graduate School of Medicine Osaka University
2012 - JPRN-UMIN000007845 Japan;
Department of Rheumatology &
Osaka University
2017 - JPRN-UMIN000025940 Japan;
Osaka Unversity
2014 - JPRN-UMIN000025943 Japan;
Shanghai Zhongshan Hospital
2020 Phase 4 NCT04300686 China;
2016 - NCT03893136 China;
Tocilizumab (MRA-SC)
Chugai Pharmaceutical Co., Ltd.
2014 Phase 3 JPRN-JapicCTI-142616 Japan;
Tofacitinib
Chinese SLE Treatment And Research Group
2022 Phase 4 NCT05151848 China;
Tofacitinib tablet
Shanghai Zhongshan Hospital
2020 Phase 4 NCT04299971 China;
Upadacitinib
AbbVie
2020 Phase 3 NCT04161898 Japan;Korea, Republic of;Turkey;
Ustekinumab
Janssen Pharmaceutical K.K.
2021 Phase 3 NCT04882072 Japan;
Numaguchi Hirotaka
2021 Phase 3 JPRN-jRCT2061210007 Japan;
Yellow Fever vaccine (17D)
University of Sao Paulo General Hospital
2018 - NCT03430388 Brazil;